Why the study?
Screening and treatment of AF could prevent about 12% of all strokes, but existing low-cost devices only measure ECG or pulse over short periods, limiting prolonged AF detection.
Do wearable devices (AliveCor, WatchBP, Polar H7, Firstbeat Bodyguard 2) accurately detect atrial fibrillation compared to a 12-lead ECG in primary care patients aged 65 and over?
Case-Control (n=421)
Double-blind (nurses, investigators, and cardiologists blinded to pre-existing AF status)
Random sequence of device testing
Yes
Do wearable devices (AliveCor, WatchBP, Polar H7, Firstbeat Bodyguard 2) accurately detect atrial fibrillation compared to a 12-lead ECG in primary care patients aged 65 and over?
Answers are grounded in this paper and cite their sources.
This protocol outlines a multicenter case-control study to evaluate the diagnostic accuracy and acceptability of four wearable devices for atrial fibrillation screening in primary care.
INTRODUCTION: Atrial fibrillation (AF) is a cause of stroke and a marker of atherosclerosis and of all patients with stroke, around 17% have AF. The screening and treatment of AF could prevent about 12% of all strokes. Several relatively low-cost devices with good accuracy now exist which can detect AF including WatchBP and AliveCor. However, they can only measure the ECG or pulse over short time periods. Inexpensive devices such as heart rate monitors, which are widely available, can measure heart rate for prolonged periods and may have potential in screening for AF. This study aims to determine the accuracy of AliveCor and WatchBP along with a bespoke algorithm using a heart rate monitor belt (Polar H7) and a wearable RR interval recorder (Firstbeat Bodyguard 2) for detecting AF during a single screening visit in primary care patients. METHODS/ANALYSIS: A multicentre case-control diagnostic study comparing the four different devices for the detection of AF with a reference standard consisting of a 12-lead ECG in GP surgeries across Hampshire, UK. We aim to recruit 92 participants with AF and 329 without AF aged 65 years and over. We will ask participants to rate comfort and overall impression for each device. We will collect qualitative data from participants capturing their experience of using wearable devices in order to evaluate acceptability. We will collect data from GPs to determine their views on AF screening. ETHICS AND DISSEMINATION: This protocol was approved by the London-City & East Research Ethics Committee in June 2016. The findings of the trial will be disseminated through peer-reviewed journals, national and international conference presentations and the Atrial Fibrillation Association, UK. TRIAL REGISTRATION NUMBER: ISRCTN17495003, Pre-results.
No takes yet. Share an insight, caveat, or question.
Lown et al. (2017) conducted a case-control in Atrial Fibrillation (n=421). AliveCor, WatchBP, Polar H7, and Firstbeat Bodyguard 2 vs. 12-lead ECG was evaluated on Diagnostic accuracy (sensitivity and specificity) of four devices against 12-lead ECG for the detection of AF.
Synapse has enriched 10 related papers. Consider them for comparative context: